Valuation: Precision BioSciences, Inc.

Market Cap 28Cr 26Cr 24Cr 22Cr 40Cr 2.62TCr 43Cr 288.52Cr 114.67Cr 1.43TCr 105.98Cr 103.75Cr 4.48TCr P/E 2026 *
-2.6x
P/E 2027 * -3.38x
Enterprise Value 28Cr 26Cr 24Cr 22Cr 40Cr 2.62TCr 43Cr 288.52Cr 114.67Cr 1.43TCr 105.98Cr 103.75Cr 4.48TCr EV / Sales 2026 *
24.9x
EV / Sales 2027 * 32.3x
Free-Float
94.12%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision BioSciences, Inc.

1 day+7.09%
1 week-2.18%
Current month+4.82%
1 month+10.28%
3 months-16.38%
6 months+3.50%
Current year+77.88%
1 week 6.73
Extreme 6.73
7.64
1 month 6.29
Extreme 6.29
11.29
Current year 3.53
Extreme 3.53
11.29
1 year 3.53
Extreme 3.53
11.29
3 years 3.53
Extreme 3.53
19.43
5 years 3.53
Extreme 3.53
289.2
10 years 3.53
Extreme 3.53
710.11
Manager TitleAgeSince
Chief Executive Officer 48 15/10/2021
Chief Tech/Sci/R&D Officer 53 26/01/2006
Director of Finance/CFO 45 01/08/2026
Director TitleAgeSince
Chairman 68 01/11/2020
Director/Board Member 65 10/03/2020
Director/Board Member 67 12/04/2021
Date Insider Type Main position Quantity % Market Cap. Importance
28/09/26 Buy

Director

1,000 0.0042%
25/09/26 Buy

Director

2,609 0.0108%
25/09/26 Buy

Director

1,135 0.0047%
Change 5-day change 1-year change 3-year change Capi.($)
+7.09%-2.18%+48.00%-41.23% 28Cr
-2.49%-3.76%+53.38%+62.10% 6.37TCr
-0.63%-2.91%+6.55%+89.34% 5.86TCr
-2.37%-2.22%+21.77%+84.58% 5.42TCr
-2.19%-6.15%+12.43%+111.40% 4.47TCr
-1.89%-7.28%+9.30%+18.50% 4.05TCr
-0.93%-0.47%+19.34%+41.83% 3.63TCr
+1.11%-6.44%+127.46%+675.37% 3.49TCr
-0.80%+0.61%+76.27%+61.80% 3.23TCr
-2.17%+16.65%-28.89%+479.93% 3.1TCr
Average -0.53%-1.31%+34.56%+158.36% 4TCr
Weighted average by Cap. -1.47%-1.85%+31.84%+155.00%

Financials

2026 *2027 *
Net sales 1.13Cr 1.03Cr 95.23L 86.63L 1.63Cr 105.08Cr 1.71Cr 12Cr 4.61Cr 57Cr 4.26Cr 4.17Cr 180.12Cr 87.4L 79.6L 73.35L 66.72L 1.25Cr 81Cr 1.32Cr 8.93Cr 3.55Cr 44Cr 3.28Cr 3.21Cr 138.73Cr
Net income -8.06Cr -7.34Cr -6.77Cr -6.15Cr -12Cr -746.56Cr -12Cr -82Cr -33Cr -407.77Cr -30Cr -30Cr -1.28TCr -9.3Cr -8.47Cr -7.81Cr -7.1Cr -13Cr -861.19Cr -14Cr -95Cr -38Cr -470.38Cr -35Cr -34Cr -1.48TCr
Net Debt - -
Projected Income Statement - Annual - Precision BioSciences, Inc.
Logo Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline comprises in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is an in vivo gene editing program which targets and eliminates covalently closed circular DNA (cccDNA), the sole source of viral replication, leading to sustained loss of pre-genomic RNA (pgRNA), the precursor for hepatitis B virus (HBV) DNA. ELIMINATE-B is designed to be a curative treatment for chronic hepatitis B infection.
Employees
69
Date Price Change Volume
20/26/20 $7.400 +7.09% 4,29,797
19/26/19 $6.910 -2.68% 2,69,173
18/26/18 $7.100 +0.71% 3,70,343
17/26/17 $7.050 -3.16% 3,50,990
16/26/16 $7.280 -3.77% 2,04,412
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Precision BioSciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.400USD
Average target price
29.40USD
Spread / Average Target
+297.30%
  1. Stock Market
  2. Stocks
  3. DTIL Stock